All In Biotech

Investigational drug · Phase 3

Orelabrutinib

Also called: ICP-022

Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

11

9 still active

All registered trials

115

Any phase or sponsor naming "Orelabrutinib"

First trial start

2019

Nov 18, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Orelabrutinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Mantle Cell Lymphoma
  • Part 1:r/r B-cell Malignancies
  • Part 2:B-cell Malignancies
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Multiple Sclerosis (MS) Primary Progressive
  • Relapsed/Refractory Marginal Zone Lymphoma (MZL)
  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)
  • Secondary Progressive Multiple Sclerosis
  • Hematologic Malignancies
  • Treatment-naїve Mantle Cell Lymphoma

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Multiple sclerosis · Hematology and blood cancers · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Orelabrutinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 106 on PubMed

Also in development for Mantle Cell Lymphoma

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • NemtabrutinibMK-1026, ARQ 531Phase 36 trials

    Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

  • RocbrutinibLP-168, NWP-775Phase 36 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma

  • TacabrutidegBGB-16673Phase 36 trials

    BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • Relma-celCAR, CD19-targeted Chimeric Antigen Receptor T CellsPhase 23 trials

    Shanghai Ming Ju Biotechnology Co., Ltd. · Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

  • CYT-0851Phase 21 trial

    Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.